Bottom line
What is MDVAX's expense ratio?
MDVAX's expense ratio is 1.09%, or about $109 a year on every $10,000 invested. That is more expensive than 76% of core / intermediate bond funds we track (median 0.71%). This share class also charges a front-end sales load of up to 4.25%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Jan 30, 2026
MDVAX fee table
| Net expense ratio | 1.09% |
|---|---|
| Gross expense ratio | 1.22% |
| Management fee | 0.4% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.57% |
| Fee waiver / reimbursement | -0.13% |
| Max front-end sales load | 4.25% |
| Max deferred sales charge | 1% |
Source: Fund prospectus fee table, filed Jan 30, 2026
What MDVAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| MDVAX | $531 | $783 | $1,055 | $1,829 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.09% expense ratio costs roughly $59,900 in lost growth, versus about $40,300 for the median core / intermediate bond fund (0.71%).